Erlotinib Associated Trichomegaly In A Patient With Chronic Latanoprost UseJournal: Journal of Hematology and Oncology Research (Vol.1, No. 4)
Publication Date: 2015-15-08
Authors : Burris CK; Richards NQ; Cowan CL Jr;
Page : 37-41
Keywords : trichomegaly; oncology;
Trichomegaly is a known adverse effect with the epidermal growth factor receptor inhibitor (EGFRI) and prostaglandin analogue drug classes. We present a chronic Latanoprost user who developed symptomatic trichomegaly subsequent to initiating an EGFRI medication and believe this case offers evidence that the two classes of medications may cause a similar eyelash manifestation through different mechanisms.
Other Latest Articles
Last modified: 2015-12-12 15:40:49